GM-CSF in the treatment of Fanconi's anaemia.
We have used recombinant human (rh) GM-CSF in two 12-year-old Fanconi's aplastic anaemia patients. They had not received any previous therapy except blood transfusions. Each patient was given three 21 d courses of rh-GM-CSF, the first two at a dose of 3.5 micrograms/kg/d and the third at 7 micrograms/kg/d s.c. There were significant increases in WBC and absolute neutrophil counts after the first week of rh-GM-CSF which lasted as long as the treatment was continued. Following the cessation of treatment, WBC and ANC dropped rapidly. We conclude that rh-GM-CSF can be used in FAA, especially in severely neutropenic cases.
Kemahli
S
S
Department of Paediatrics and Paediatric Haematology, Faculty of Medicine, Ankara University, Turkey.
Canatan
D
D
Uysal
Z
Z
Akar
N
N
Cin
S
S
Arcasoy
A
A
D002648:Child; D005199:Fanconi Anemia / Q000097:blood / Q000628:therapy*; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006454:Hemoglobins; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D009504:Neutrophils; D011994:Recombinant Proteins / Q000627:therapeutic use
D006454:Hemoglobins; D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor